首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1937029

全球癌症惡病質市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Cancer Cachexia Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 138 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計癌症惡病質市場將從 2025 年的 30.5 億美元成長到 2034 年的 48.7 億美元，2026 年至 2034 年的複合年成長率為 5.34%。

由於癌症患者數量不斷增加，以及人們對惡病質作為癌症嚴重併發症的認知不斷提高，癌症惡病質市場預計將迎來顯著成長。癌症惡病質是一種多因素症候群，其特徵是體重顯著下降、肌肉萎縮和身體機能狀態惡化，嚴重影響患者的生活品質和治療效果。隨著醫療專業人員和研究人員認知到在癌症治療中解決惡病質問題的重要性，對有效治療方法和管理策略的需求預計將會增加，從而推動該市場的強勁成長。目前的治療方案包括旨在改善食慾和肌肉量的營養干預、藥物和支持性護理。

此外，對癌症惡病質潛在機制的研究和理解不斷深入，正在推動市場創新。識別與惡病質相關的特定生物標記和通路，為開發能夠更有效地治療該疾病的標靶治療鋪平了道路。例如，抗發炎藥物和合成代謝類固醇作為潛在治療方案的研究已引起廣泛關注。隨著研究的不斷深入和對惡病質生物學機制新認知的不斷揭示，市場有望進一步擴張，並有望改善患者的治療效果和生活品質。

此外，癌症治療中多面向綜合方法的重要性日益凸顯，也正在重塑癌症惡病質的治療模式。隨著醫療服務提供者越來越認知到將營養支持、物理治療和心理護理融入癌症治療方案的重要性，對綜合惡病質管理方案的需求預計將會成長。這一趨勢在個人化醫療的背景下尤其重要，因為個人化的干涉措施可以顯著提高癌症治療的有效性。隨著癌症惡病質治療市場的不斷發展，治療方案的創新組合、對綜合患者護理的重視以及持續的研究將在推動未來成長方面發揮關鍵作用。

區域分析
北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 其他亞太國家
拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家

第8章競爭情勢

最新趨勢
公司分類
供應鏈和銷售管道合作夥伴（根據現有資訊）
市場佔有率和市場定位分析（基於現有資訊）
供應商格局（基於現有資訊）
策略規劃

第9章：公司簡介

主要公司的市佔率分析
公司簡介
- Aeterna Zentaris Inc
- Alder BioPharmaceuticals Inc
- Aphios Corporation
- Eli Lilly And Company
- GTxInc
- Helsinn Group
- Merck & Co. Inc
- Novartis AG
- Bristol-Myers Squibb Company
- XBiotech Inc

簡介目錄

Product Code: VMR11214594

The Cancer Cachexia Market size is expected to reach USD 4.87 Billion in 2034 from USD 3.05 Billion (2025) growing at a CAGR of 5.34% during 2026-2034.

The cancer cachexia market is poised for significant growth, driven by the increasing prevalence of cancer and the rising awareness of cachexia as a serious complication associated with the disease. Cancer cachexia is a multifactorial syndrome characterized by severe weight loss, muscle wasting, and a decline in overall health, significantly impacting patients' quality of life and treatment outcomes. As healthcare providers and researchers recognize the importance of addressing cachexia in cancer care, the demand for effective therapies and management strategies is expected to rise, positioning this market for robust expansion. Current treatment options include nutritional interventions, pharmacological agents, and supportive care measures aimed at improving appetite and muscle mass.

Moreover, advancements in research and understanding of the underlying mechanisms of cancer cachexia are driving innovation within the market. The identification of specific biomarkers and pathways involved in cachexia is paving the way for the development of targeted therapies that can more effectively address this condition. For instance, the exploration of anti-inflammatory agents and anabolic steroids is gaining traction as potential treatment options. As research continues to uncover new insights into the biology of cachexia, the market is likely to expand further, driven by the promise of improved patient outcomes and quality of life.

Additionally, the growing emphasis on multidisciplinary approaches to cancer care is shaping the cancer cachexia landscape. As healthcare providers increasingly recognize the importance of integrating nutritional support, physical therapy, and psychological care into cancer treatment plans, the demand for comprehensive cachexia management solutions is likely to increase. This trend is particularly relevant in the context of personalized medicine, where tailored interventions can significantly enhance the effectiveness of cancer therapies. As the cancer cachexia market continues to evolve, the combination of innovative treatment options, a focus on holistic patient care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

Progestogens
Corticosteroids
Combination Therapies
Others

By Mechanism of Action

Appetite Stimulators
Weight Loss Stabilizers
Others

By Distribution Channel

Hospital Stores
Retail Pharmacy Stores
Online Pharmacies

COMPANIES PROFILED

Aeterna Zentaris Inc, Alder BioPharmaceuticals Inc, Aphios Corporation, Eli Lilly and Company, GTxInc, Helsinn Group, Merck Co Inc, Novartis AG, BristolMyers Squibb Company, XBiotech Inc

We can customise the report as per your requriements

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER CACHEXIA MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Therapeutics
4.2. Progestogens Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Combination Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER CACHEXIA MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Mechanism Of Action
5.2. Appetite Stimulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Weight Loss Stabilizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER CACHEXIA MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Distribution Channel
6.2. Hospital Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Retail Pharmacy Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER CACHEXIA MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Therapeutics
- 7.2.2 By Mechanism Of Action
- 7.2.3 By Distribution Channel
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Therapeutics
- 7.3.2 By Mechanism Of Action
- 7.3.3 By Distribution Channel
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Therapeutics
- 7.4.2 By Mechanism Of Action
- 7.4.3 By Distribution Channel
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Therapeutics
- 7.5.2 By Mechanism Of Action
- 7.5.3 By Distribution Channel
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Therapeutics
- 7.6.2 By Mechanism Of Action
- 7.6.3 By Distribution Channel
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER CACHEXIA INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Aeterna Zentaris Inc
- 9.2.2 Alder BioPharmaceuticals Inc
- 9.2.3 Aphios Corporation
- 9.2.4 Eli Lilly And Company
- 9.2.5 GTxInc
- 9.2.6 Helsinn Group
- 9.2.7 Merck & Co. Inc
- 9.2.8 Novartis AG
- 9.2.9 Bristol-Myers Squibb Company
- 9.2.10 XBiotech Inc